See more : Hanmi Pharm. Co., Ltd. (128940.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Guobang Pharma Ltd. (605507.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guobang Pharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sichuan Zigong Conveying Machine Group Co., Ltd. (001288.SZ) Income Statement Analysis – Financial Results
- 9342-8530 Québec Inc. (DGCRF) Income Statement Analysis – Financial Results
- RENK Group AG (R3NK.DE) Income Statement Analysis – Financial Results
- Buffalo Coal Corp. (BUC.JO) Income Statement Analysis – Financial Results
- UPM-Kymmene Oyj (RPL.DE) Income Statement Analysis – Financial Results
Guobang Pharma Ltd. (605507.SS)
About Guobang Pharma Ltd.
Guobang Pharma Ltd. engages in the research and development, production, and sale of medical products for human and animals in China. It offers medical products, including APIs, medication intermediates related to the API, and formulations; and veterinary products, such as APIs for animals, additives, and formulations. The company was founded in 1996 and is based in Xinchang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.35B | 5.72B | 4.51B | 4.21B | 3.80B | 3.28B | 2.91B |
| Cost of Revenue | 4.14B | 4.14B | 3.15B | 2.76B | 2.82B | 2.30B | 2.06B |
| Gross Profit | 1.21B | 1.58B | 1.36B | 1.45B | 986.20M | 974.69M | 841.01M |
| Gross Profit Ratio | 22.60% | 27.55% | 30.14% | 34.49% | 25.94% | 29.73% | 28.95% |
| Research & Development | 191.99M | 197.54M | 155.27M | 137.19M | 124.34M | 103.30M | 94.73M |
| General & Administrative | 107.43M | 91.50M | 91.57M | 60.19M | 53.14M | 45.09M | 139.59M |
| Selling & Marketing | 46.68M | 64.15M | 55.86M | 74.89M | 76.66M | 70.76M | 61.49M |
| SG&A | 358.08M | 155.66M | 147.43M | 135.08M | 129.81M | 115.85M | 201.08M |
| Other Expenses | -43.49M | 221.86M | 176.28M | 148.59M | 140.43M | -17.86M | -16.43M |
| Operating Expenses | 506.59M | 575.06M | 478.98M | 420.86M | 394.58M | 353.76M | 313.77M |
| Cost & Expenses | 4.65B | 4.72B | 3.63B | 3.18B | 3.21B | 2.66B | 2.38B |
| Interest Income | 51.78M | 29.36M | 18.38M | 13.62M | 17.83M | 22.84M | 0.00 |
| Interest Expense | 27.54M | 16.55M | 28.72M | 35.52M | 33.74M | 33.21M | 5.04M |
| Depreciation & Amortization | 322.37M | 261.79M | 202.31M | 157.87M | 139.03M | 133.01M | 115.52M |
| EBITDA | 1.05B | 1.31B | 1.04B | 1.14B | 748.70M | 728.05M | 601.96M |
| EBITDA Ratio | 19.58% | 23.53% | 24.03% | 27.37% | 19.68% | 23.88% | 21.40% |
| Operating Income | 702.26M | 1.05B | 808.77M | 936.12M | 581.59M | 579.69M | 469.33M |
| Operating Income Ratio | 13.13% | 18.40% | 17.95% | 22.26% | 15.30% | 17.68% | 16.15% |
| Total Other Income/Expenses | -4.61M | -17.24M | -1.99M | 7.32M | -5.66M | -17.86M | -16.43M |
| Income Before Tax | 697.65M | 1.04B | 806.78M | 943.44M | 575.92M | 561.83M | 452.90M |
| Income Before Tax Ratio | 13.04% | 18.10% | 17.91% | 22.43% | 15.15% | 17.13% | 15.59% |
| Income Tax Expense | 87.67M | 115.02M | 100.55M | 133.15M | 81.92M | 78.37M | 61.65M |
| Net Income | 612.46M | 920.90M | 706.03M | 810.00M | 494.01M | 210.87M | 177.73M |
| Net Income Ratio | 11.45% | 16.10% | 15.67% | 19.26% | 12.99% | 6.43% | 6.12% |
| EPS | 1.10 | 1.65 | 1.26 | 1.45 | 0.88 | 0.44 | 0.37 |
| EPS Diluted | 1.10 | 1.65 | 1.26 | 1.45 | 0.88 | 0.44 | 0.37 |
| Weighted Avg Shares Out | 556.79M | 558.82M | 558.82M | 558.82M | 558.82M | 477.19M | 477.19M |
| Weighted Avg Shares Out (Dil) | 556.79M | 558.82M | 558.82M | 558.82M | 558.82M | 477.19M | 477.19M |
Source: https://incomestatements.info
Category: Stock Reports